ESTRO 2024 - Abstract Book

S1763

Clinical - Lung

ESTRO 2024

Conclusion:

Reirradiation of an in-field lung cancer recurrence with a curative dose (median 60Gy EQD 2,10 ) is safe when using accumulated maximal doses of 75Gy EQD 2,3 , 100Gy EQD 2,3 and 110Gy EQD 2,3 to spine, esophagus and tracheobronchial tree, respectively. Within this multicenter prospective phase II trial, we report low grade 2 and 3 toxicity with an median OS of 30 months.

Keywords: Re-irradiation, lung cancer, toxicity

2640

Digital Poster

A 10-year experience of non-small cell lung cancer treated with curative-intent radiotherapy

Ashley Horne 1 , Danya Abdulwahid 1 , Kathryn Banfill 1 , Claire Barker 1 , Neil Bayman 1 , Clara Chan 1 , Joanna Coote 2 , Corinne Faivre-Finn 1 , Fabio Gomes 1 , Paul Hoey 3 , Jennifer King 1 , Laura Pemberton 1 , Hamid Sheikh 1 , Okezie Uche Ikonne 3 , David Woolf 1 , Margaret Harris 1 1 The NHS Christie Foundation Trust, Lung Oncology, Manchester, United Kingdom. 2 The NHS Christie Foundation Trust, Lu, Manchester, United Kingdom. 3 The NHS Christie Foundation Trust, Clinical Outcomes and Data Unit, Manchester, United Kingdom

Purpose/Objective:

Curative-intent radiotherapy plays a major role in the management of NSCLC. Real-word evidence is important as it can supplement clinical trial data and provide clinically relevant information for those patients typically excluded from classical trials. The newly formed Clinical Outcomes & Data Unit (CODU) at The Christie NHS Foundation Trust can generate reports extracting large amounts of patient and tumour data recorded on structured forms recorded within the electronic patient record (EPR).

Project aim: to demonstrate that the CODU team can summarise basic clinical and survival data for all patients treated with curative-dose radiotherapy at the Christie over a 10-year period.

Material/Methods:

2898 patients with NSCLC were treated with curative-intent radiotherapy (including SABR, radical radiotherapy, sequential chemoradiotherapy and concurrent chemoradiotherapy+/-consolidation durvalumab) at the Christie between 01/01/2013 to 06/09/2023. Summary statistics were produced including baseline patient characteristics (see table 1) and survival probabilities (see table 2). Patients in the radical radiotherapy cohort included patients who received radiotherapy alone and those who received induction chemotherapy prior to definitive radiotherapy.